By Josh Beckerman
Inovio Pharmaceuticals shares were down 20% to $2.99 after hours as the company said it plans to sell stock and accompanying warrants.
The company intends to use proceeds primarily for the development of its clinical pipeline, including preparing for a potential commercial launch of lead drug candidate INO-3107 if approved, and for general corporate purposes. INO-3107 is a potential treatment for recurrent respiratory papillomatosis, a benign tumor disease.
In August, Inovio filed a prospectus supplement for the potential sale of up to $60 million of stock from time to time. On April 15, it announced the pricing of a roughly $36 million offering.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 12, 2024 18:49 ET (23:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。